Roy Buchanan
Stock Analyst at JMP Securities
(3.62)
# 494
Out of 5,182 analysts
46
Total ratings
50%
Success rate
44.17%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASMB Assembly Biosciences | Initiates: Market Outperform | $38 | $29.33 | +29.56% | 1 | Sep 24, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $13.25 | +88.68% | 15 | Aug 12, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $4.24 | +230.19% | 2 | Jun 17, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $3.37 | -40.65% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.13 | +1,492.92% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $37.93 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $2.55 | +56.86% | 3 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $3.53 | +296.60% | 1 | Jan 30, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $119.47 | -72.38% | 1 | Jan 10, 2025 | |
| ABUS Arbutus Biopharma | Maintains: Market Outperform | $4 → $5 | $4.46 | +12.11% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $748.25 | -40.13% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $7.08 | +125.99% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.03 | - | 2 | Feb 16, 2023 |
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $29.33
Upside: +29.56%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $13.25
Upside: +88.68%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $4.24
Upside: +230.19%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $3.37
Upside: -40.65%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.13
Upside: +1,492.92%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $37.93
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $2.55
Upside: +56.86%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $3.53
Upside: +296.60%
ABIVAX Société Anonyme
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $119.47
Upside: -72.38%
Arbutus Biopharma
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.46
Upside: +12.11%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $748.25
Upside: -40.13%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $7.08
Upside: +125.99%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.03
Upside: -